Шаблоны LeoTheme для Joomla.
GavickPro Joomla шаблоны

banner genetics

Editorial

Sickle Cell Anemia: only one Single Point Mutation but Many Pathophysiological Issues

Danilo Grünig Humberto da Silva1*

1UNESP — Sao Paulo State University, Department of Biology, Hemoglobin and Hematologic 5 Genetic Diseases Laboratory, Sao Paulo, Brazil 6
2UNESP — Sao Paulo State University, Department of Chemistry and Environmental Sciences, 7 Sao Paulo, Brazil

*Corresponding author:  Dr. Danilo Grünig Humberto da Silva, UNESP — Sao Paulo State University, Department of Biology, 12Hemoglobin and Hematologic Genetic Diseases Laboratory, Rua Cristovão Colombo, 2265, 13 Jardim Nazareth, CEP: 15054-000, SãoJosé do Rio Preto, São Paulo, Brazil, Tel: 14 +5517 3221-2392;
E-mail: dangrunig@gmail.com

Submitted: 05-01-2015 Accepted: 05 -04-2015 Published: 05-08-2015

Download PDF

_________________________________________________________________________________________________________________________

 

Article

 

It has been 100 years since Herrick published the first medical case report of the anemia 24 describing abnormal shapes of red blood cells (RBCs) and gave sickle cell anemia (SCA) its name 25 [1]. Afterwards, Vernon Ingram [2] discovered that the defect of the disease was a single 26 aminoacid substitution in the hemoglobin (Hb) molecule (HBBglu6val), and understanding has 27 gradually increased since then. Even with improved knowledge of the human genome, 28 development of new genomic tools and identification of single nucleotide polymorphisms (SNPs) 29 associated with subphenotypes of SCA by genome-wide association studies (GWAS) [3], and 30 more than 100 different blood and urine biomarkers have been described in SCA [4]. There is still 31 a major challenge to combine all these variables and establish potential predictors of the SCA 32 severity [5]. 33

The last 60 years have resulted in an increasingly coherent detailed molecular-level 34 description of the SCA pathophysiology [6]. Despite our precise knowledge of the molecular 35 defect that is associated with hemoglobin S (HbS) in RBCs [7]. Furthermore, recent progress in 36 understanding the molecular events that control polymerization of HbS and sickling of 37 erythrocytes [8]. Nevertheless, these mechanisms are not sufficient to explain the heterogeneous 38 phenotype found among SCA patients, such as pain episodes, acute chest syndrome, neurological 39 complications, leg ulcers and other symptoms. In this way, despite HbS presence is indispensable 40 for the disease establishment, several other phenomena affected by a multitude of genes other 41 than the one directly involved (HBB*S) play an important role [9]. 42

While great progress has been made in describing the basic disease process that accounts 43 for hemolytic anemia and the obstructive events underlying vaso-occlusive events (VOE), many 44 questions remain [6]. The simple mutation in the β6-location of globin has a profound effect on 45 all tissues and organs in the SCA patient, and because the vasculopathy affects a large variety of 46 physiologic mechanisms, the varied genetic background of individual patients makes prediction 47 of the clinical severity highly complex [6]. In this way, clinical broad spectrum of SCA can be 48 affected by a number of modifying factors including the haplotype of β-globin gene cluster [10], 49 the coinheritance of polymorphisms associated with both clinical aspects [11] and treatment 50 response [3], hemoglobin fetal (Hb F) levels [12], chronic inflammation and oxidative states [13, 51 14] as well as gender, and others [10]. 52

Among the new evidences, oxidative stress processes have been increasingly related to 53 the SCA pathophysiology [4]. The increased production of prooxidant elements is caused by 54 intrinsic disease mechanisms, such as increased activity of several oxidases (NADPH oxidase and 55 endothelial xanthine oxidase) [15, 16], HbS auto-oxidation [17], heme iron release, increased 56 asymmetric dimethylarginine (ADMA) [18], uncoupling of nitric oxide synthase (NOS) activity, 57 and decreased nitric oxide (NO) levels [19]. As the antioxidant defense systems in SCD are 58 affected and/or are not sufficient to neutralize excessive production of oxidant species [20], 59 chronic oxidative stress establishes, being a critical factor in endothelial dysfunction, 60 inflammation and damage to multiple organs [21]. In this way, oxidative stress is directly related 61 to both cause and consequence of inflammation, hemolysis, vasculopathy, vaso- occlusion, 62 infection, and injury by ischemia/reperfusion, e.g. [22]. For this reason, newer therapeutic agents 63 that can target oxidative stress may constitute valuable means for preventing or delaying the 64 development of organ complications [23, 24]. Thus, antioxidant therapy is being a worthy, 65 promising and increasing goal for SCA treatment. 66

In this context, McCarty [25] suggested the use of comprehensive nutraceutical strategy 67 for mitigating the contribution of oxidative stress to SCA pathogenesis, dubbed as ‘‘full-spectrum 68 antioxidant therapy”. Many recent studies, both in vitro and in vivo, have investigated different 69 strategies as antioxidant therapy for SCA treatment [26-28]. However, paradoxical observations 70 with regard of certain prooxidant effects of antioxidant compounds have been reported under 71 some experimental conditions, indicating the complex interdependency among the pool of 72 physiological relevant cellular antioxidants [29]. Therefore, more studies focusing newer and 73 more specific oxidative stress biomarkers can be helpful to obtain better clues about effective 74 prognostic information of SCA patients. Furthermore, it may be fundamental to the development 75 of more efficacious therapeutic drugs in order to mitigate the devastating clinical manifestations 76 of SCA. 77

References

References

1.Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe 81 anemia. Yale J Biol Med. 2001, 74(3): 179-184.

2.Ingram VM. Gene mutations in human haemoglobin: the chemical difference between 83 normal and sickle cell haemoglobin. Nature. 1957, 180(4581): 326-328.

3.Fertrin KY, Costa FF. Genomic polymorphisms in sickle cell disease: implications for 85 clinical diversity and treatment. Expert Rev Hematol. 2010, 3(4) : 443–458.

4.Rees DC, Gibson JS. Biomarkers in sickle cell disease. Br J Haematol. 2012, 156(4): 433-445.

5.Lettre G. The search for genetic modifiers of disease severity in the beta-88 hemoglobinopathies. Cold Spring Harb Perspect Med. 2012, 2(10): 1-12.

6.Kuypers FA. Hemoglobin s polymerization and red cell membrane changes. Hematol 90 Oncol Clin North Am 2014, 28(2): 155-179.

7.Christoph GW, Hofrichter J, Eaton WA. Understanding the shape of sickled red cells. 92 Biophys. J 2005, 88(2): 1371- 1376.

8.Ferrone FA. Polymerization and Sickle Cell Disease: A Molecular View. 94 Microcirculation. 2004, 11(2): 115-128.

9.Nagel RL. Severity, pathobiology, epistatic effects, and genetic markers in sickle cell 96 anemia. Semin Hematol. 1991, 28(3): 180-201.

10.Kulozik AE, Wainscoat JS, Serjeant GR, Kar BC, Al-Awamy B et al. Geographical 99 Survey of βS-Globin Gene Haplotypes: Evidence for an Independent Asian Origin of the Sickle-100 Cell Mutation. Am J Hum Genet. 1986, 39(2): 239-44.

11.Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005, 129(4): 465-481.

12.Steinberg ME. Management of sickle cell disease. N Engl J Med. 1999, 340(13): 1021-1030.

13.Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of 105 sickle cell disease vaso-occlusion. Hemoglobin 2009, 33(1): 1-16.

14.Fibach E, Rachmilewitz E. The Role of Oxidative Stress in Hemolytic Anemia. Curr Mol 107 Med. 2008, 8(7): 609-19. 108

15.Aslan M, Ryan TM, Adler B, Townes TM, Parks DA et al. Oxygen radical inhibition 110 of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 111 2001, 98(26): 15215-15220.

16.Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the 113 cerebral microvascular dysfunction in sickle cell transgenic mice. The FASEB Journal 114. 2005, 19(8): 989-991.

17.Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical 116 generation by sickle erythrocytes. J Clin Invest. 1982, 70(6): 1253-9.

18.Landburg PP, Teerlink T, Biemond BJ, Brandjes DP, Muskiet FA et al.118 Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the 119 hemolytic phenotype. Blood Cells Mol Dis. 2010, 44(4): 229-232.

19.Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC et al. Dysregulated arginine metabolism, hemolysis-122 associated pulmonary hypertension, and mortality in sickle cell disease. Jama. 2005, 294(1): 81-90.

20.Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C et al. Red blood cells, platelets 124 and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress 125 that can be ameliorated by antioxidants. Br J Haematol. 2006, 132(1): 108-113.

21.Hebbel* RP, Osarogiagbon R, Kaul D. The Endothelial Biology of Sickle Cell Disease: 127 Inflammation and a Chronic Vasculopathy. Microcirculation. 2004, 11(2): 129-151.

22.Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. The Lancet. 2010, 376(9597): 2018-2031.

23.Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen 130 metabolites. Clin. Exp. Pharmacol. Physiol. 2007, 34(9): 926-932.

24.Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJ. Oxidative stress in 132 sickle cell disease; pathophysiology and potential implications for disease management. Am J 133 Hematol. 2011, 86(6): 484-489.

25.McCarty MF. Potential utility of full-spectrum antioxidant therapy, citrulline, and dietary 135 nitrate in the management of sickle cell disease. Med Hypotheses. 2010, 74(6): 1055- 1058.

26.Vichinsky E. Emerging ‘A’ therapies in hemoglobinopathies: agonists, antagonists, 137 antioxidants, and arginine. Hematology Am Soc Hematol Educ Program. 2012, 2012: 271-5.

27.Silva DG, Belini Junior E, de Almeida EA, Bonini-Domingos CR. Oxidative stress in 139 sickle cell disease: an overview of erythrocyte redox metabolism and current antioxidant 140 therapeutic strategies. Free Radic Biol Med. 2013, 65: 1101- 1109.

28.Silva DGH, Júnior-Ricci O, Almeida EA, Bonini-Domingos CR. Potential utility of 142 melatonin as an antioxidant therapy in the management of sickle cell anemia. J Pineal Res 143. 2015, 58(2): 178–188.

29.Chan AC, Chow CK, Chiu D. Interaction of antioxidants and their implication in genetic 145 anemia. Proc Soc Exp Biol Med. 1999, 222 (3): 274-282.

Cite this article: da Silva DGH. Sickle Cell Anemia: only one Single Point Mutation but Many Pathophysiological Issues. J J Genetics. 2015, 1(1): 003.

 

Contact Us:
9600 GREAT HILLS
TRAIL # 150 W
AUSTIN, TEXAS
78759 ( TRAVIS COUNTY)
E-mail : info@jacobspublishers.com
Phone : 512-400-0398